September 2026
M	T	W	T	F	S	S
	1	2	3	4	5	6
7	8	9	10	11	12	13
14	15	16	17	18	19	20
21	22	23	24	25	26	27
28	29	30

Mohammed Alo: The Gap Between Nattokinase Marketing and Evidence

Mohammed Alo/LinkedIn

Jun 21, 2026, 05:23

Mohammed Alo: The Gap Between Nattokinase Marketing and Evidence

Mohammed Alo, Fellow of the American College of Cardiology at American College of Cardiology, shared a post on LinkedIn:

“Nattokinase will not unclog your arteries.

Supplement companies are selling you a $40 bottle of false hope while your plaques keep growing.

But the data says otherwise.

And no, they are not just ‘natural enzymes that dissolve clots.’

What you are actually dealing with:

Atherosclerosis is not a kitchen drain clogged with grease. You cannot pour an enzyme down your coronary artery and watch the blockage dissolve.

Plaques are complex structures. Fibrous caps. Lipid cores. Calcified deposits. Inflammatory cells. A fermented soybean extract is not touching any of that.

Yet the online grifters are selling nattokinase as if it is the secret your cardiologist does not want you to know. They are wrong. And the silence from the cardiology literature is not a conspiracy. It is a verdict.

I am a board-certified cardiologist.

I am America’s Cardiologist.

I have treated thousands of patients with established coronary artery disease, acute MI, and high-risk atherosclerosis. I have never once seen nattokinase on a peer-reviewed guideline. Not in the ACC. Not in the AHA. Not anywhere that answers to evidence.

Here is what the science actually says:

The research on nattokinase comes almost entirely from rat studies and in vitro models. Rats are not humans.

Test tubes are not arteries. An enzyme that shows fibrinolytic activity in a petri dish does not automatically translate to clinical benefit in a living, breathing patient with decades of plaque burden.

The human trial data is thin, small, and nowhere near the scale required to make the claims supplement marketers are making.

We are talking about studies with dozens of participants, no cardiovascular outcome data, and zero evidence that nattokinase reduces heart attacks, strokes, or cardiovascular death.

That is not promising. That is not ’emerging.’ That is insufficient.

Now contrast that with what we actually know works.”

Mohammed Alo: The Gap Between Nattokinase Marketing and Evidence